Related references
Note: Only part of the references are listed.miR-126 regulates platelet-derived growth factor receptor-alpha expression and migration of primary human osteoblasts
Yvonne Schmidt et al.
BIOLOGICAL CHEMISTRY (2015)
Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma
Anne S. Tsao et al.
ANNALS OF DIAGNOSTIC PATHOLOGY (2014)
Prognostic Impact of Major Receptor Tyrosine Kinase Expression in Gastric Cancer
Yukinori Kurokawa et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
MicroRNA-34A inhibits the growth, invasion and metastasis of gastric cancer by targeting PDGFR and MET expression
Yang Peng et al.
BIOSCIENCE REPORTS (2014)
Biomimetic nanoparticles for siRNA delivery in the treatment of leukaemia
Jianfeng Guo et al.
BIOTECHNOLOGY ADVANCES (2014)
Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants
Allison Galanis et al.
BLOOD (2014)
A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors
Carlos R. Becerra et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Phase I study of olaratumab in Japanese patients with advanced solid tumors
Toshihiko Doi et al.
CANCER SCIENCE (2014)
miR-34a regulates mesangial cell proliferation via the PDGFR-β/Ras-MAPK signaling pathway
Dapeng Chen et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2014)
PDGF receptor signaling networks in normal and cancer cells
Jean-Baptiste Demoulin et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2014)
Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA
Irina Sadovnik et al.
EXPERIMENTAL HEMATOLOGY (2014)
Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Identification and elimination of target-related matrix interference in a neutralizing anti-drug antibody assay
Martin Schwickart et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2014)
Inhibition of Receptor Signaling and of Glioblastoma-derived Tumor Growth by a Novel PDGFRβ Aptamer
Simona Camorani et al.
MOLECULAR THERAPY (2014)
The roles of platelet-derived growth factors and their receptors in brain radiation necrosis
Tomo Miyata et al.
RADIATION ONCOLOGY (2014)
Crenolanib is a selective type I pan-FLT3 inhibitor
Catherine Choy Smith et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Therapeutic potential of siRNA and DNAzymes in cancer
Hanuma Kumar Karnati et al.
TUMOR BIOLOGY (2014)
Crenolanib, a PDGFR inhibitor, suppresses lung cancer cell proliferation and inhibits tumor growth in vivo
Ping Wang et al.
ONCOTARGETS AND THERAPY (2014)
Antiangiogenic cancer drug sunitinib exhibits unexpected proangiogenic effects on endothelial cells
Kerri-Ann Norton et al.
ONCOTARGETS AND THERAPY (2014)
The VEGF- and PDGF-family of angiogenic markers have prognostic impact in soft tissue sarcomas arising in the extremities and trunk
Thomas K. Kilvaer et al.
BMC CLINICAL PATHOLOGY (2014)
A Recurrent PDGFRB Mutation Causes Familial Infantile Myofibromatosis
Yee Him Cheung et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2013)
Platelet-derived growth factors and their receptors: Structural and functional perspectives
Po-Han Chen et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2013)
Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib
Jie Dai et al.
CLINICAL CANCER RESEARCH (2013)
Pazopanib as Second-Line Treatment After Sunitinib or Bevacizumab in Patients With Advanced Renal Cell Carcinoma: A Sarah Cannon Oncology Research Consortium Phase II Trial
John D. Hainsworth et al.
CLINICAL GENITOURINARY CANCER (2013)
Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies
M. R. Matrana et al.
EUROPEAN JOURNAL OF CANCER (2013)
Identification of novel FLT3 kinase inhibitors
Daphnie Pauwels et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2013)
Therapeutic RNA aptamers in clinical trials
Padma Sundaram et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2013)
Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma
Jie Sheng Chu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2013)
Non-small cell lung cancer cells survived ionizing radiation treatment display cancer stem cell and epithelial-mesenchymal transition phenotypes
Roberto Gomez-Casal et al.
MOLECULAR CANCER (2013)
Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial
Yoon-Koo Kang et al.
LANCET ONCOLOGY (2013)
Multifarious functions of PDGFs and PDGFRs in tumor growth and metastasis
Yihai Cao
TRENDS IN MOLECULAR MEDICINE (2013)
Blockade of the PDGFR family together with SRC leads to diminished proliferation of colorectal cancer cells
Silke Kaulfuss et al.
ONCOTARGET (2013)
Acquired resistance to drugs targeting receptor tyrosine kinases
Steven A. Rosenzweig
BIOCHEMICAL PHARMACOLOGY (2012)
Physical-chemical principles underlying RTK activation, and their implications for human disease
Lijuan He et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2012)
Discovery of AZD2932, a new Quinazoline Ether Inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases
Patrick A. Ple et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
RNA aptamers as highly specific inhibitors of three human RTKs including Axl, EGFR and PDGFR
Carla Lucia Esposito et al.
CANCER RESEARCH (2012)
Recent advances and novel agents for gastrointestinal stromal tumor (GIST)
Gurpreet Lamba et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2012)
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Winette T. A. van der Graaf et al.
LANCET (2012)
Targeting Axl With an High-affinity Inhibitory Aptamer
Laura Cerchia et al.
MOLECULAR THERAPY (2012)
A comparative study of PDGFR inhibition with imatinib on radiolabeled antibody targeting and clearance in two pathologically distinct models of colon adenocarcinoma
Vineeth S. Rajkumar et al.
TUMOR BIOLOGY (2012)
Mutation in the platelet-derived growth factor receptor alpha inhibits adeno-associated virus type 5 transduction
Ingo H. Pilz et al.
VIROLOGY (2012)
Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab
Christine Vestergaard Madsen et al.
JOURNAL OF OVARIAN RESEARCH (2012)
RNA interference: A futuristic tool and its therapeutic applications
Anghesom Ambesajir et al.
SAUDI JOURNAL OF BIOLOGICAL SCIENCES (2012)
Trial watch Monoclonal antibodies in cancer therapy
Lorenzo Galluzzi et al.
ONCOIMMUNOLOGY (2012)
Experience with sorafenib in the treatment of advanced renal cell carcinoma
Giuseppe Procopio et al.
THERAPEUTIC ADVANCES IN UROLOGY (2012)
Multitargeted receptor tyrosine kinase inhibition: An antiangiogenic strategy in non-small cell lung cancer
Mark A. Socinski
CANCER TREATMENT REVIEWS (2011)
PDGF-D Improves Drug Delivery and Efficacy via Vascular Normalization, But Promotes Lymphatic Metastasis by Activating CXCR4 in Breast Cancer
Jieqiong Liu et al.
CLINICAL CANCER RESEARCH (2011)
Immunohistochemical Overexpression of Platelet-Derived Growth Factor Receptor-Beta (PDGFR-β) is Associated With PDGFRB Gene Copy Number Gain in Sarcomatoid Non-Small-Cell Lung Cancer
Anne S. Tsao et al.
CLINICAL LUNG CANCER (2011)
Pazopanib: Clinical development of a potent anti-angiogenic drug
Fabio A. B. Schutz et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2011)
Adaptor protein Lnk binds to PDGF receptor and inhibits PDGF-dependent signaling
Saskia Gueller et al.
EXPERIMENTAL HEMATOLOGY (2011)
Sorafenib for the management of advanced renal cell carcinoma
Bernard Escudier
EXPERT REVIEW OF ANTICANCER THERAPY (2011)
Platelet-derived growth factor and platelet-derived growth factor receptor-α expression in the normal human thymus and thymoma
Anca Maria Cimpean et al.
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY (2011)
MicroRNA-9 is an activation-induced regulator of PDGFR-beta expression in cardiomyocytes
Jianhu Zhang et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2011)
Vascular endothelial growth factors and receptors: Anti-angiogenic therapy in the treatment of cancer
Sonia Tugues et al.
MOLECULAR ASPECTS OF MEDICINE (2011)
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
Hagop M. Kantarjian et al.
LANCET ONCOLOGY (2011)
Discovery and Development of Therapeutic Aptamers
P. R. Bouchard et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2010)
New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases
Federica Toffalini et al.
BLOOD (2010)
Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models
Chunhua Lu et al.
CANCER BIOLOGY & THERAPY (2010)
Targeting the α Receptor for Platelet-Derived Growth Factor as a Primary or Combination Therapy in a Preclinical Model of Prostate Cancer Skeletal Metastasis
Mike R. Russell et al.
CLINICAL CANCER RESEARCH (2010)
Phase I study of MEDI-575, a fully human monoclonal antibody targeting PDGFR-alpha in subjects with advanced solid tumors
R. Lechleider et al.
EJC SUPPLEMENTS (2010)
Towards a targeted multi-drug delivery approach to improve therapeutic efficacy in breast cancer
Bin Wang et al.
EXPERT OPINION ON DRUG DELIVERY (2010)
PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas
Tatsuya Ozawa et al.
GENES & DEVELOPMENT (2010)
A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer
Michael Friedlander et al.
GYNECOLOGIC ONCOLOGY (2010)
First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
Guoqing Wei et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2010)
Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide
Gregor Dresemann et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study
Keith C. Bible et al.
LANCET ONCOLOGY (2010)
A Phase II Study of Pazopanib in Patients with Recurrent or Metastatic Invasive Breast Carcinoma: A Trial of the Princess Margaret Hospital Phase II Consortium
Sara K. Taylor et al.
ONCOLOGIST (2010)
Prognostic Significance of Stromal Platelet-Derived Growth Factor β-Receptor Expression in Human Breast Cancer
Janna Paulsson et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR β signalling
Marion T. Weigel et al.
CANCER LETTERS (2009)
Differential roles of PDGFR-alpha and PDGFR-beta in angiogenesis and vessel stability
Junhang Zhang et al.
FASEB JOURNAL (2009)
Response to a Novel Multitargeted Tyrosine Kinase Inhibitor Pazopanib in Metastatic Merkel Cell Carcinoma
Matthew Davids et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Immunotherapy in the landscape of new targeted treatments for non-small cell lung cancer
Catherine Gerard et al.
MOLECULAR ONCOLOGY (2009)
RNAi screen for rapid therapeutic target identification in leukemia patients
Jeffrey W. Tyner et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Development of a Fully Human Anti-PDGFR beta Antibody That Suppresses Growth of Human Tumor Xenografts and Enhances Antitumor Activity of an Anti-VEGFR2 Antibody
Juqun Shen et al.
NEOPLASIA (2009)
Targeting cancer with small molecule kinase inhibitors
Jianming Zhang et al.
NATURE REVIEWS CANCER (2009)
Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma
Tadahiko Kubo et al.
CANCER (2008)
Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer
Sherry X. Yang et al.
CLINICAL CANCER RESEARCH (2008)
Role of platelet-derived growth factors in physiology and medicine
Johanna Andrae et al.
GENES & DEVELOPMENT (2008)
Phase II trial of sorafenib in advanced thyroid cancer
Vandana Gupta-Abramson et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
RNA interference targeting the platelet-derived growth factor receptor β subunit ameliorates experimental hepatic fibrosis in rats
Si-Wen Chen et al.
LIVER INTERNATIONAL (2008)
MicroRNA Mirn140 modulates Pdgf signaling during palatogenesis
Johann K. Eberhart et al.
NATURE GENETICS (2008)
Role of PDGF in fibrotic diseases and systemic sclerosis
M. Trojanowska
RHEUMATOLOGY (2008)
A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A children's oncology group study
Mason Bond et al.
PEDIATRIC BLOOD & CANCER (2008)
Targeted chronic myeloid leukemia therapy: Seeking a cure
Christopher Fausel
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2007)
PDGF BB induces VEGF secretion in ovarian cancer
Daniela Matei et al.
CANCER BIOLOGY & THERAPY (2007)
An antibody directed against PDGF receptor β enhances the antitumor and the anti-angiogenic activities of an anti-VEGF receptor 2 antibody
Juqun Shen et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Aptamers-based assays for diagnostics, environmental and food analysis
Sara Tombelli et al.
BIOMOLECULAR ENGINEERING (2007)
The molecular pathogenesis of gastrointestinal stromal tumors
Chi Tarn et al.
CLINICAL COLORECTAL CANCER (2006)
Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: A study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG)
Martine Van Glabbeke et al.
EUROPEAN JOURNAL OF CANCER (2006)
Autocrine PDGFR signaling promotes mammary cancer metastasis
Martin Jechlinger et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Mutational analysis of PDGFR-RAS/MAPK pathway activation in childhood medulloblastoma
RJ Gilbertson et al.
EUROPEAN JOURNAL OF CANCER (2006)
Phase II placebo-controlled randomized discontinuation trial of sorafnib in patients with metastatic renal cell carcinoma
Mark J. Ratain et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Comparing antibody and small-molecule therapies for cancer
Kohzoh Imai et al.
NATURE REVIEWS CANCER (2006)
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastorna multiforme
DA Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Anticancer therapeutics: Addictive targets, multi-targeted drugs, new drug combinations
HJ Broxterman et al.
DRUG RESISTANCE UPDATES (2005)
A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer
S Modi et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
PDGFR-alpha signaling is critical for tooth cusp and palate morphogenesis
X Xu et al.
DEVELOPMENTAL DYNAMICS (2005)
Endothelium-specific ablation of PDGFB leads to pericyte loss and glomerular, cardiac and placental abnormalities
M Bjarnegård et al.
DEVELOPMENT (2004)
Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors
MD Hofer et al.
NEOPLASIA (2004)
Stable expression of small interfering RNA sensitizes TEL-PDGFβR to inhibition with imatinib or rapamycin
J Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
Identification of PDGFR as a receptor for AAV-5 transduction
G Di Pasquale et al.
NATURE MEDICINE (2003)
Human brain tumor-derived PDGFR-α deletion mutant is transforming
ID Clarke et al.
ONCOGENE (2003)
Receptor tyrosine kinases in normal and malignant haematopoiesis
JT Reilly
BLOOD REVIEWS (2003)
Leydig cell loss and spermatogenic arrest in platelet-derived growth factor (PDGF)-A-deficient mice
L Gnessi et al.
JOURNAL OF CELL BIOLOGY (2000)
Share Paper
